Applied Therapeutics (Applied Therapeutics) Additional Paid-In Capital : $451.43 Mil(As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Applied Therapeutics Additional Paid-In Capital?

Applied Therapeutics's quarterly additional paid-in capital increased from Jun. 2023 ($384.20 Mil) to Sep. 2023 ($419.86 Mil) and increased from Sep. 2023 ($419.86 Mil) to Dec. 2023 ($451.43 Mil).

Applied Therapeutics's annual additional paid-in capital increased from Dec. 2021 ($328.96 Mil) to Dec. 2022 ($352.83 Mil) and increased from Dec. 2022 ($352.83 Mil) to Dec. 2023 ($451.43 Mil).

Applied Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Applied Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Therapeutics Additional Paid-In Capital Chart

Applied Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

99.38

242.78

328.96

352.83

451.43

Applied Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															352.83	354.88	384.20	419.86	451.43

Applied Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Applied Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Applied Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied Therapeutics (Applied Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Therapeutics Inc (NAS:APLT) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

2UV:Germany

Address

545 Fifth Avenue, Suite 1400, New York, NY, USA, 10017

Website

https://www.appliedtherapeutics.com

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need.

Executives

Stacy J. Kanter	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Shoshana Shendelman	director, 10 percent owner, officer: President and CEO	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Adam Hansard	officer: Chief Commercial Officer	C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE, SUITE 1400, NEW YORK NY 10017
Riccardo Perfetti	officer: Chief Medical Officer	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Alexandria Real Estate Equities, Inc.	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101
Catherine Thorpe	officer: Chief Accounting Officer	545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Chids Mahadevan	officer: Chief Accounting Officer	C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Steven A. Ortega	officer: Principal Accounting Officer	C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Charles Silberstein	officer: Chief Financial Officer	C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Leslie D. Funtleyder	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Joel S Marcus	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Alexandria Equities No. 7, Llc	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101
Jay S Skyler	director	DANCE BIOPHARM INC., 150 NORTH HILL DRIVE, SUITE 24, BRISBANE CA 94005
Alexandria Venture Investments, Llc	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101
Teena Lerner	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173